|
|
Article: Sepracor Reports That Schering-Plough Applies For Broader Clarinex(TM) Indication in United States For Treatment of Allergic Rhinitis.
- Article from:
- PR Newswire
- Article date:
- April 16, 2001
CopyrightCOPYRIGHT 2001 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Broader Claim Covers Seasonal Allergic Rhinitis and Perennial Allergic
Rhinitis
MARLBOROUGH, Mass., April 16 /PRNewswire/ --
Sepracor Inc. (Nasdaq: SEPR) today reported that Schering-Plough Corporation (NYSE: SGP) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking to broaden the allergy indication for its nonsedating antihistamine, CLARINEX(TM) (desloratadine) 5 mg Tablets. The proposed indication of allergic rhinitis would encompass both seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR). The allergic rhinitis NDA is based on eight randomized, placebo-controlled studies ...